33 completed, 3 withdrawn, 2 terminated, 1 not yet recruiting. 31 Phase 1, 7 Phase 2, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 31 | Completed 27, Withdrawn 2, Not yet recruiting 1, Suspended 1 |
| Phase 2 | 7 | Completed 3, Terminated 2, Recruiting 1, Withdrawn 1 |
| Not applicable | 2 | Completed 2 |
Follow HIV Vaccine Trials Network: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected 426c.Mod.Core-C4b, 3M-052-AF, Aluminum hydroxide suspension (Alum) - HIV Infections | Phase 1 | Not yet recruiting | HIV Vaccine Trials Network | 22 | 2027-03-30 | 2026-09-18 |
| Evaluating the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibodies in Healthy Participants VRC01.23LS, PGT121.414.LS, PGDM1400LS - HIV Infections | Phase 1 | Suspended | HIV Vaccine Trials Network | 77 | 2024-08-14 | 2024-07-05 |
| Evaluating the Safety and Immunogenicity of MTBVAC MTBVAC, BCG - HIV I Infection, Tuberculosis | Phase 2 | Recruiting | HIV Vaccine Trials Network | 276 | 2024-01-30 | 2026-03-12 |
| To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV VIR-1388, Placebo - HIV I Infection | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 93 | 2023-09-19 | 2026-03-03 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV sD-NP-GT8 DNA, IL-12 DNA, Trimer 4571 - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 46 | 2023-04-10 | 2025-11-14 |
| Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study Analytical Treatment Interruption - HIV Infection | Not applicable | Completed | HIV Vaccine Trials Network | 18 | 2022-08-22 | 2025-04-20 |
| Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult. AdC6-HIVgp140, AdC7-HIVgp140, CH505TF gp120 - HIV Infections | Phase 1 | Completed | HIV Vaccine Trials Network | 34 | 2021-11-25 | 2025-12-24 |
| Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study Analytical Treatment Interruption - HIV Infection | Not applicable | Completed | HIV Vaccine Trials Network | 13 | 2021-05-28 | 2026-03-13 |
| Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants PGT121.414.LS, VRC07-523LS - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 33 | 2020-11-10 | 2024-12-13 |
| Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants CH505TF gp120, GLA-SE adjuvant, Placebo - HIV Infections | Phase 1 | Completed | HIV Vaccine Trials Network | 38 | 2020-11-10 | 2026-01-29 |
| Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 Sample collection - SARS-CoV-2, COVID-19 | Completed | HIV Vaccine Trials Network | 760 | 2020-05-13 | 2026-01-12 | |
| Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults BG505 SOSIP.664 gp140, Placebo, 3M-052-AF - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 127 | 2020-01-13 | 2025-09-02 |
| Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine ALVAC-HIV (vCP2438), Bivalent Subtype C gp120/MF59, Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension - HIV Infections | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 132 | 2017-06-19 | 2026-07-24 |
| Safety and Immune Response to a Clade C DNA HIV Vaccine DNA-HIV-PT123 vaccine, Protein/MF59 vaccine, Placebo - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 132 | 2016-06-21 | 2019-06-21 |
| Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents H4:IC31, H56:IC31, BCG - Tuberculosis | Phase 1 | Completed | Aeras | 84 | 2015-05-01 | 2019-11-18 |
| A Safety and Immune Response Study of 2 Experimental HIV Vaccines ALVAC-HIV, Bivalent Subtype C gp120/MF59®, ALVAC-HIV (vCP2438) Placebo - HIV Infection | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 252 | 2015-02-02 | 2021-11-05 |
| Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults DNA Nat-B env, DNA CON-S env, DNA Mosaic env - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 105 | 2014-12-01 | 2023-04-24 |
| Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults ALVAC-HIV, AIDSVAX B/E, Placebo for ALVAC-HIV - HIV Infection | Phase 1 | Completed | HIV Vaccine Trials Network | 202 | 2013-06-18 | 2019-06-21 |
| Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults DNA-HIV-PT123, NYVAC-HIV-PT1, NYVAC-HIV-PT4 - HIV Infections | Phase 1 | Completed | HIV Vaccine Trials Network | 96 | 2012-08-01 | 2015-03-25 |
| Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults MVA-C + gp140/MF59, DNA-C2 + MVA-C, DNA-C2 + MVA-C + gp140/MF59 - HIV Seronegativity, HIV Preventive Vaccine | Phase 1 | Completed | HIV Vaccine Trials Network | 184 | 2011-12-19 | 2019-06-21 |
Showing 20 of 41. Sign in to see all of them.
HIV Infections (37) · Adenoviridae Infections (5) · Acquired Immunodeficiency Syndrome (3) · Tuberculosis (2) · COVID-19 (1) · Disease Progression (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Lentivirus Infections (1) · RNA Virus Infections (1) · Retroviridae Infections (1) · Sexually Transmitted Diseases (1) · Sexually Transmitted Diseases, Viral (1) · Slow Virus Diseases (1) · Virus Diseases (1)
AIDSVAX (4) · aluminum sulfate (3) · Observation (2) · Vaccines, DNA (2) · 1018 oligonucleotide (1) · AIDSVAX B-E (1) · Engerix-B (1) · HIV Envelope Protein gp120 (1) · Hepatitis B Vaccines (1) · Interleukin-12 (1) · Interleukin-15 (1) · MTBVAC vaccine (1) · Product Labeling (1) · Sodium Chloride (1) · Specimen Handling (1)
South Africa (22) · United States (20) · Peru (5) · Switzerland (3) · Zimbabwe (3) · Botswana (2) · Brazil (2) · Malawi (2) · Zambia (2) · Dominican Republic (1) · Haiti (1) · Kenya (1) · Mozambique (1) · Puerto Rico (1) · Rwanda (1)
Shelly Karuna (3) · Glenda Gray, MD (2) · Jonathan Fuchs, MD, MPH (2) · Katharine Bar (2) · Linda-Gail Bekker, MD (2) · Lindsey Baden (2) · Magdalena Sobieszczyk (2) · Pierre-Alexandre Bart, MD (2) · Salim Abdool Karim, MD, PhD (2) · Ameena Goga (1) · Amy Violari (1) · Ann Duerr, MD, PhD, MPH (1) · Avy Violari (1) · Beryl Koblin, PhD (1)
PMID 40190112, PMID 22914365, PMID 23349878, PMID 25820067, PMID 31999736, PMID 34843602, PMID 34895272, PMID 20636279, PMID 20854108, PMID 21343146, PMID 21533229, PMID 21570355, PMID 21860356, PMID 21931737, PMID 22532824, PMID 22561365, PMID 23878319, PMID 24099601, PMID 24560541, PMID 25271627, PMID 25401780, PMID 26368824, PMID 26833336, PMID 26951820, PMID 27098021, PMID 27583368, PMID 28131393, PMID 29898870, PMID 31601541, PMID 31900486, PMID 32092060, PMID 32382714, PMID 34850742, PMID 34871308, PMID 36787249, PMID 37352144, PMID 38502656, PMID 39302924, PMID 39484284, PMID 39667379, PMID 40178906, PMID 40462491
UM1AI068614 (6), U01AI068614 (2), 5UM1AI068614-14 (1), 5UM1AI068614-18 (1), P01AI049364 (1)